I do remember our back and forth on those two slides, now that you mention it. I also remember having trouble posting the article/slideset as well. Apparently CCO finally opened the article to public view. At least I’m going with that. Could it be I didn’t know what I was doing the first time? Nah.... 

Oh, I am so glad to see you are able to post this thing here in it's entirety!  It IS a great wholistic resource. It's the same info we have been drawing on from time to time this year - in part, namely the long back and forths Angel and I touched on when comparing the potency of Mavyret to Vosevi - (recall the info from table #23 and #24 that did get posted and discussed and bantered about back and forth?). #23 and 24 had such compelling "activity" (potency) comparisons between the NS5A's in Mavyret and Vosevi (PIB versus VEL) and impressive potency comparisons between the NS3/4A's in Mav and Vosevi (Glec versus VOX). So it's nice to see the whole of this thing here on the site as a resource. I had such trouble trying to get even getting a couple of the slidesets to stick/post.  C. 

This slide set was published last year, but offers some interesting info for new and old members alike. I couldn’t locate it being brought here before and CCO is more often a physician only periodical most don’t have access to. It’s amazing to see the shear numbers affected by this disease globally and how that number breaks down demographically.

HCV Tools for Care

Thanks to CCO